Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H2 2019’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

– The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects

– The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Aduro BioTech Inc

Affimed GmbH

Agios Pharmaceuticals Inc

AlfaSigma SpA

Alissa Pharma

Angiocrine Bioscience Inc

Anhui Anke Biotechnology (Group) Co Ltd

Apollomics Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

BeiGene Ltd

Biohaven Pharmaceutical Holding Company Ltd

Bristol-Myers Squibb Co

Carrick Therapeutics Ltd

Catalent Inc

Celgene Corp

Cell Medica Ltd

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellectis SA

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Celularity Inc

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Constellation Pharmaceuticals Inc

CSL Ltd

CStone Pharmaceuticals Co Ltd

Curis Inc

Eutilex Co Ltd

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Gibson Oncology LLC

Harbin Gloria Pharmaceuticals Co Ltd

Hebei Senlang Biotechnology Inc Ltd

Helocyte Biosciences Inc

HRAIN Biotechnology Co Ltd

Immune Cell Inc

Immunomedics Inc

Incuron LLC

Incyte Corp

Inhibrx Inc

Kite Pharma Inc

Magenta Therapeutics Inc

Marker Therapeutics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

NantKwest Inc

NBE-Therapeutics AG

NewBio Therapeutics Inc

Northlake International LLC

OncoTartis Inc

Protheragen Inc

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Rich Pharmaceuticals Inc

Rizen (Suzhou) Biosciences Co Ltd

Sanofi

Seattle Genetics Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Shattuck Labs Inc

Sichuan Kelun Pharmaceutical Co Ltd

SpecificiT Pharma Inc

Stemline Therapeutics Inc

Syndax Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Taiwan Liposome Co Ltd

Trillium Therapeutics Inc

Tyme Technologies Inc

Wuhan Bio-Raid Biotechnology Co Ltd

Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd”

Table of Contents

Table of Contents

Introduction

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Actinium Pharmaceuticals Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics SA, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aduro BioTech Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Agios Pharmaceuticals Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AlfaSigma SpA, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alissa Pharma, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Angiocrine Bioscience Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Apollomics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Astellas Pharma Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AstraZeneca Plc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Avipep Pty Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by BeiGene Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Co, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Carrick Therapeutics Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Catalent Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celgene Corp, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cell Medica Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celldex Therapeutics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectar Biosciences Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellestia Biotech AG, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celularity Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkmate Pharmaceuticals Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Checkpoint Therapeutics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Chipscreen Biosciences Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Constellation Pharmaceuticals Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CSL Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Eutilex Co Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Gibson Oncology LLC, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Helocyte Biosciences Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by HRAIN Biotechnology Co Ltd, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immune Cell Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Immunomedics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incuron LLC, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Inhibrx Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kite Pharma Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Magenta Therapeutics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Marker Therapeutics Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, H2 2019

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports